Evidence map›Paper›PMID 26444110›Full record

ArticleObstetrics and gynecology2015

Changes in Use of Long-Acting Reversible Contraceptive Methods Among U.S. Women, 2009-2012.

Megan L Kavanaugh, Jenna Jerman, Lawrence B Finer

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Obstetrics and gynecology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 112 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 3 pooled it
42.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03519685 nacompletednot on this mapstarted 2018, after this paper: background citation

UCSF College Health Study: A Cluster Randomized Trial on Contraceptive Training and Education at Community Colleges

TypeinterventionalSponsorUniversity of California, San FranciscoRan2018 to 2024Enrolled2,086ConditionsContraceptionArmsContraceptive Training and Education, Placebo Nutrition Education
NCT03868137 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Multi-dose Ibuprofen Prophylaxis for IUD-insertion (MIPI): A Triple Blinded

TypeinterventionalSponsorOrlando VA Medical CenterRan2020 to 2022Enrolled86ConditionsPelvic Pain, IUDArmsIbuprofen, Placebos
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 3 syntheses or guidelines pooled it, 282 citations in OpenAlex.

  1. Pooled it
  2. Progestin-only contraceptives: effects on weight.The Cochrane database of systematic reviews · 2016
    Pooled it
  3. Hormonal contraceptives for contraception in overweight or obese women.The Cochrane database of systematic reviews · 2016
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Long-Acting Reversible Contraception Counseling and Use for Older Adolescents and Nulliparous Women.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2016
    Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Megan L KavanaughGuttmacher Institute, Research Division, New York, New York.
Jenna Jerman
Lawrence B Finer
Guttmacher Institute · US

Funding

Research Infrastructure for Demographic and Behavioral Population Science Dissemination CoreR24HD074034 · NICHD · GUTTMACHER INSTITUTE · PI FINER, LAWRENCE B · 2013 to 2017
$462k
NICHD NIH HHS R24 HD074034
6 · The paper itself

Abstract

objectiveTo examine current levels, current correlates of, and changes in long-acting reversible contraceptive (LARC) use, including intrauterine devices and implants, among females aged 15-44 years using contraception between 2008-2010 and 2011-2013 with specific attention to associations between race, income, and age and their LARC use.

methodsWe analyzed data from two rounds of the National Survey of Family Growth, nationally representative samples of females aged 15-44 years, consisting of 6,428 females in 2008-2010 and 5,601 females in 2011-2013. We conducted simple and multivariable logistic regression analyses with adjustments for the sampling design to identify demographic characteristics predictive of LARC use and changes in these patterns between the two time periods. In this cross-sectional, descriptive study, our primary outcome of interest was current prevalence of LARC use among all contraceptive users at the time of the interview.

resultsThe prevalence of LARC use among contracepting U.S. females increased from 8.5% in 2009 to 11.6% in 2012 (P<.01). The most significant increases occurred among Hispanic females (from 8.5% to 15.1%), those with private insurance (7.1-11.1%), those with fewer than two sexual partners in the previous year (9.2-12.4%), and those who were nulliparous (2.1-5.9%) (all P<.01). In multivariable analyses adjusting for key demographic characteristics, the strongest associations with LARC use in 2012 were parity (adjusted odds ratios [ORs] 4.3-5.5) and having a history of stopping non-LARC hormonal use (adjusted OR 1.9). Women aged 35-44 years (adjusted OR 0.3) were less likely to be LARC users than their counterparts (all P<.001). Poverty status was not associated with LARC use. There were no differences in discontinuation of LARC methods resulting from dissatisfaction between minority women and non-Hispanic white women.

conclusionDuring the most recent time period surveyed, use of LARC methods, particularly intrauterine devices, increased almost uniformly across the population of users. LEVEL OF EVIDENCE: III.

Indexed as

AdolescentAdultContraceptionContraceptive Agents, FemaleCross-Sectional StudiesDrug ImplantsFemaleHumansIntrauterine DevicesUnited StatesYoung AdultContraceptive Agents, FemaleDrug Implants

Identifiers

PMID26444110
PMCPMC4946164
OpenAlexW2246934237

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.